Jasper rises on promising early-stage data for lead product candidate

Jasper Therapeutics

13/01/2023 14:27

** Shares of biotech co Jasper Therapeutics Inc  JSPR.O 
jump 32.12% premarket to $2.18, among top pct gainers across
U.S. exchanges trading before the bell
    ** Co says its lead product candidate briquilimab was safe,
well-tolerated and led to durable remissions in 8 of the first
12 patients AML patients treated at one-year follow up
    ** The early-stage trial tested briquilimab in combination
with cancer therapy Fludarabine and low-toxicity radiation in
patients between ages 62-79 years with blood cancers, acute
myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
undergoing stem cell transplant
    ** JSPR says 29 AML and MDS patients also achieved lower
than expected rates of severe acute and chronic graft-vs-host
disease, a complication that can occur after a stem cell or bone
marrow transplant in which the newly transplanted donor cells
attack the transplant recipient's body
    ** Co on Tuesday had said it does not have near-term plans
to initiate a late-stage trial for briquilimab in blood cancers 
   ** Co lost ~74% in the last 12 months
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))